<DOC>
	<DOC>NCT00145236</DOC>
	<brief_summary>The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension.</brief_summary>
	<brief_title>Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension</brief_title>
	<detailed_description>This study was a Phase II, 12-week multicenter, randomized, double-blind, parallel group, placebo-controlled study of nebivolol over a range of doses in Black patients with mild to moderate hypertension. Treatment was administered once daily (qd) for 12 weeks. The study consisted of 2 phases: (1) screening/washout/single-blind placebo run-in and (2) randomization/treatment. Patients had 7 scheduled clinic visits during the study (6 clinic visits for patients not on current antihypertensive medication).</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Black adults with an average sitting diastolic blood pressure of greater then or equal to 95 mmHg and less then or equal to 109 mmHg at baseline. Recent myocardial infarction or stroke Contraindication to betablocker therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>Beta-Blocker</keyword>
</DOC>